Search

Your search keyword '"Gilkes, Amanda"' showing total 326 results

Search Constraints

Start Over You searched for: Author "Gilkes, Amanda" Remove constraint Author: "Gilkes, Amanda"
326 results on '"Gilkes, Amanda"'

Search Results

1. Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial

2. Risk Stratification in Older Intensively Treated Patients With AML

Catalog

Books, media, physical & digital resources

3. Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML

4. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML

5. Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial

7. A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial

8. Overlapping features of therapy-related and de novo NPM1-mutated AML

10. Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

11. Unified classification and risk-stratification in Acute Myeloid Leukemia

16. Molecular MRD status and outcome after transplantation in NPM1-mutated AML

17. Post induction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

19. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

20. Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations

21. Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

22. P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL

23. S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL

24. P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES

26. S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL

27. Postinduction molecular MRD identifies patients with NPM1AML who benefit from allogeneic transplant in first remission

28. An international standardization programme towards the application of gene expression profiling in routine leukaemia diagnostics: the Microarray Innovations in LEukemia study prephase

30. Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

31. Nuclear factor I-C overexpression promotes monocytic development and cell survival in acute myeloid leukemia

32. Pretransplant FLT3-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcome

33. FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

34. Development of a Standardized, DNA-Based Next Generation Sequencing Assay for Assessment of Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) As the Primary Endpoint in the Agility Study

35. Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

36. Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction

37. A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

38. Protein Kinase C Epsilon Overexpression Is Associated With Poor Patient Outcomes in AML and Promotes Daunorubicin Resistance Through p-Glycoprotein-Mediated Drug Efflux

39. FLT3inhibitors as MRD-guided salvage treatment for molecular failure in FLT3mutated AML

40. Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

42. Unified classification and risk-stratification in Acute Myeloid Leukemia

43. Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)

44. Assessment of Minimal Residual Disease in Standard-Risk AML

45. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

46. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA

47. A novel algorithmic approach to generate consensus treatment guidelines in adult acute myeloid leukaemia

48. High Sensitivity Detection of FLT3-ITD Measurable Residual Disease By Deep Sequencing Prior to Hematopoietic Cell Transplant Is Highly Prognostic for Outcome in Acute Myeloid Leukemia

49. MRD Directed Treatment Intensification with Either FLAG-Ida or DA-Cladribine Improves Survival in Older AML Patients: Results from the NCRI AML18 Randomised Trial